These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24954473)

  • 1. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates.
    Chuah MK; Petrus I; De Bleser P; Le Guiner C; Gernoux G; Adjali O; Nair N; Willems J; Evens H; Rincon MY; Matrai J; Di Matteo M; Samara-Kuko E; Yan B; Acosta-Sanchez A; Meliani A; Cherel G; Blouin V; Christophe O; Moullier P; Mingozzi F; VandenDriessche T
    Mol Ther; 2014 Sep; 22(9):1605-13. PubMed ID: 24954473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy.
    Rincon MY; Sarcar S; Danso-Abeam D; Keyaerts M; Matrai J; Samara-Kuko E; Acosta-Sanchez A; Athanasopoulos T; Dickson G; Lahoutte T; De Bleser P; VandenDriessche T; Chuah MK
    Mol Ther; 2015 Jan; 23(1):43-52. PubMed ID: 25195597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy.
    Nair N; Rincon MY; Evens H; Sarcar S; Dastidar S; Samara-Kuko E; Ghandeharian O; Man Viecelli H; Thöny B; De Bleser P; VandenDriessche T; Chuah MK
    Blood; 2014 May; 123(20):3195-9. PubMed ID: 24637359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.
    Jayandharan GR; Zhong L; Sack BK; Rivers AE; Li M; Li B; Herzog RW; Srivastava A
    Hum Gene Ther; 2010 Mar; 21(3):271-83. PubMed ID: 19788390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation muscle-directed gene therapy by in silico vector design.
    Sarcar S; Tulalamba W; Rincon MY; Tipanee J; Pham HQ; Evens H; Boon D; Samara-Kuko E; Keyaerts M; Loperfido M; Berardi E; Jarmin S; In't Veld P; Dickson G; Lahoutte T; Sampaolesi M; De Bleser P; VandenDriessche T; Chuah MK
    Nat Commun; 2019 Jan; 10(1):492. PubMed ID: 30700722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing transduction of the liver by adeno-associated viral vectors.
    Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
    Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques.
    Chan JKY; Gil-Farina I; Johana N; Rosales C; Tan YW; Ceiler J; Mcintosh J; Ogden B; Waddington SN; Schmidt M; Biswas A; Choolani M; Nathwani AC; Mattar CNZ
    FASEB J; 2019 Mar; 33(3):3954-3967. PubMed ID: 30517034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.
    Mimuro J; Mizukami H; Hishikawa S; Ikemoto T; Ishiwata A; Sakata A; Ohmori T; Madoiwa S; Ono F; Ozawa K; Sakata Y
    Mol Ther; 2013 Feb; 21(2):318-23. PubMed ID: 23247100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
    Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
    Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
    Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
    J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice.
    Xu L; Daly T; Gao C; Flotte TR; Song S; Byrne BJ; Sands MS; Parker Ponder K
    Hum Gene Ther; 2001 Mar; 12(5):563-73. PubMed ID: 11268288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
    Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
    Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
    Kim HS; Kim JC; Lee YK; Kim JS; Park YS
    J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
    Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
    Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.